Vancouver, B.C. / TheNewswire / January 18, 2017 – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, has
announced appointment of Mr. Yari Nieken as a director of the company.
Mr. Nieken replaces Dr. Dom Spina who sadly passed away in December of
2016.
Mr. Nieken has a wide range of public company
and capital market experience. He is Founder and President of Foremost
Capital Inc. an Exempt Market Dealer. He is currently a director of
Marapharm Ventures Inc. and has served on the boards of several public
and private issuers including PUF Ventures (President & CEO),
Lexagene Holdings Inc. (Director), Duport Capital Ltd (Director) and has
raised substantial capital in his career. He holds an MBA from the
Sydney Graduate School of Management and a BA from the University of
British Columbia. He was formerly an investment advisor at Union
Securities Corp. and continues to be a registrant in good standing in
the provinces of British Columbia, Alberta, and Ontario.
Veritas’ CEO, Dr. Franciosi, commented, “I
would like to welcome Mr. Nieken to the Veritas team and I am looking
forward to working with him. Mr. Nieken brings a great wealth of
experience to the company, specifically in areas of capital markets,
growth strategies, and marketing. With the scientific work progressing
rapidly and having now secured the necessary financing, Mr. Nieken’s
experience will be very valuable as Veritas prepares to embark on its
next steps of its journey.”
Mr. Nieken commented, “I am extremely excited
to be joining the Board of Directors at Veritas Pharma. I believe that
Veritas Pharma is uniquely positioned for growth within a very exciting
segment of the pharmaceutical industry, and I am committed to
contributing to this growth to the best of my abilities.”
About Veritas Pharma Inc.
Veritas Pharma Inc. is an emerging-stage pharmaceutical and IP
development company, who, through Cannevert Therapeutics Ltd. (CTL), is
advancing the science behind medical cannabis. It is the Company aim,
through its investment in CTL, to develop the most effective cannabis
strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving
the critical need for clinical data to support medical marijuana
claims. CTL’s unique value proposition uses a low-cost research and
development model to help drive shareholder value, and speed-to-market.
Veritas investment in CTL is led by strong management team, bringing
together veteran academic pharmacologists, anesthetists & chemists.
The company’s commercial mission is to patent protect CTL’s IP
(cultivars & strains) and sell or license to cancer clinics,
insurance industry and pharma, targeting multi-billion dollar global
markets.
About Cannevert Therapeutics Ltd.
CTL is a private company owned by a unique group of chemists,
pharmacologists, and other medical professionals. With offices located
on the campus of the University of British Columbia, CTL has obtained
permission from Health Canada to conduct research on cannabis strains.
CTL has entered a funding agreement with Veritas where, upon advancing
$1.5 million to CTL, Veritas will earn an 80% ownership interest in CTL.
Although Veritas has advanced $1,000,000 to CTL, no ownership interest
will be earned by Veritas until the entire $1.5 million is received. CTL
has also entered a licensing agreement with Veritas, licensing Veritas
to market all products developed by CTL.
Veritas Pharma Inc. is a publicly traded
company which trades in three countries including Canada, on the
Canadian Stock Exchange under the ticker VRT; in the United States, on
the OTC under the ticker VRTHF; and in Germany, on the Frankfurt
exchange under the ticker 2VP.
For more information, please visit our website: www.veritaspharmainc.com
On behalf of the Board of Directors; Veritas Pharma Inc.
“Dr. Lui Franciosi”
Dr. Lui Franciosi
Chief Executive Officer
Further information about the Company is available on our website at
www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com
and on the CSE website at
www.thecse.com
Investor and Public Relations Contact
Veritas Pharma Inc.
Sam Eskandari
Telephone: +1.416.918.6785
Email: [email protected]
Website: www.veritaspharmainc.com
The CSE has not reviewed, nor approved or disapproved the content of this press release.
In the interest of full disclosure, we call the reader’s
attention to the fact that Equities.com, Inc. is compensated by the
companies profiled in the Spotlight Companies section. The purpose of
these profiles is to provide awareness of these companies to investors
in the micro, small-cap and growth equity community and should not in
any way be considered as a recommendation to buy, sell or hold these
securities. Equities.com is not a registered broker dealer, investment
advisor, financial analyst, investment banker or other investment
professional. We are a publisher of original and third party news and
information. All profiles are based on information that is available to
the public. The information contained herein should not be considered to
be complete and is not guaranteed by Equities.com to be free from
misstatement or errors. The views expressed are our own and not intended
to be the basis for any investment decision. Readers are reminded to do
their own due diligence when researching any companies mentioned on
this website. Always bear in mind that investing in early-stage
companies is risky and you are encouraged to only invest an amount that
you can afford to lose completely without any change in your lifestyle.
Equities has been compensated with cash, common shares and/or warrants
for market awareness services provided.
Read Next
